Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: We aim to evaluate the malignancy risk between Janus kinase inhibitors (JAKi) users and tumor necrosis factor inhibitors (TNFi) users in rheumatoid arthritis (RA) patients, using a large real-world electronic health record database (TriNetX).
Methods: In this retrospective cohort study, we identified adult RA patients initiating JAKi or TNFi therapy between January 1, 2018, and December 31, 2022, within the TriNetX global federated network. The hazard ratio (HR) and confidence intervals (CI) of incident-specific cancers, overall cancer incidence, and all-cause mortality, were calculated between the propensity score matched JAKi and TNFi cohorts. The probability of the outcome of interest was estimated using the Kaplan-Meier analysis.
Results: After propensity score matching, there were 4045 each in JAKi or TNFi user cohorts. The mean (standard deviation) age was 57.7 (13.3) and 57.6 (13.9) years, 81.4% and 80.8% were female, and median (interquartile range) follow-up time 3.69 (2.61) years vs 3.69 (2.68) years, in the JAKi and the TNFi cohorts, respectively. No significant differences were observed in risks of overall cancer incidence and all-cause mortality between the two cohorts. JAKi users had a reduced risk of incident digestive organ cancers compared with TNFi users (adjusted HR: 0.599, 95% CI: 0.439-0.817), mainly observed among females. The risks of incident respiratory and intrathoracic organs cancers were increased in JAKi users compared to TNFi users among females (adjusted HR: 2.582, 95% CI: 1.109-6.011) but not in males.
Conclusion: In a large real-world database, we did not find an increased risk of overall cancer incidence in JAKi compared to TNFi users among RA patients. JAKi users had a lower risk of incident digestive organs cancers, and a higher risk of respiratory cancer in females, when compared with TNFi users.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12409337 | PMC |
| http://dx.doi.org/10.2147/BTT.S532668 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative Cancer Incidence by Organ Site in Rheumatoid Arthritis Treated with Janus Kinase Inhibitors versus Tumor Necrosis Factor Inhibitors: A Retrospective Real-World Cohort Analysis.
Biologics
August 2025
Department of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
Objective: We aim to evaluate the malignancy risk between Janus kinase inhibitors (JAKi) users and tumor necrosis factor inhibitors (TNFi) users in rheumatoid arthritis (RA) patients, using a large real-world electronic health record database (TriNetX).
Methods: In this retrospective cohort study, we identified adult RA patients initiating JAKi or TNFi therapy between January 1, 2018, and December 31, 2022, within the TriNetX global federated network. The hazard ratio (HR) and confidence intervals (CI) of incident-specific cancers, overall cancer incidence, and all-cause mortality, were calculated between the propensity score matched JAKi and TNFi cohorts.
Survival Outcomes and Prognostic Factors in Rheumatoid Arthritis Patients Receiving Biologic or Targeted Synthetic Therapy: Real-World Data.
Antibodies (Basel)
June 2025
First Department of Internal Medicine, Faculty of Medicine, Medical University-Varna, 9002 Varna, Bulgaria.
Objectives: The present study aimed to evaluate the long-term survival of patients with rheumatoid arthritis (RA) receiving biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in a real-world setting, and to identify key prognostic factors influencing mortality within this cohort.
Methods: This retrospective, observational cohort study analyzed 165 patients with confirmed RA who were on b/tsDMARD treatment for at least six months as of June 2017. Patient data, including demographics, disease duration, prior therapeutic regimens, and global functional status were extracted from medical records to collect data covering a seven-year follow-up period, extending from June 2017 to December 2024.
Risk of non-bacterial opportunistic infections associated with janus kinase inhibitors versus tumor necrosis factor inhibitors among rheumatoid arthritis patients: A cohort study.
Joint Bone Spine
July 2025
Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea. Electronic address:
Objective: To compare the risk of serious opportunistic infections between janus kinase inhibitors (JAKis) versus tumor necrosis factor inhibitors (TNFis) among rheumatoid arthritis (RA) patients.
Methods: Using 2009-2020 Korea National Health Insurance Service database, we conducted a cohort study on RA patients initiating a JAKi or TNFi. The primary outcome was a composite of hospitalized viral, fungal, and tuberculous infections.
The Association between Tumor Necrosis Factor-Alpha Inhibitor Use and Dementia Risk in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Gerontology
June 2025
College of Pharmacy, Yeungnam University, Gyeongsan, Republic of Korea.
Introduction: Tumor necrosis factor-alpha inhibitors (TNFi), commonly prescribed for rheumatoid arthritis (RA), have been studied for their potential association with dementia risk. However, previous findings are inconclusive. This study aimed to evaluate the impact of TNFi use on dementia in patients with RA.
View Article and Find Full Text PDFPharmacogenomics of TNF inhibitors.
Front Immunol
June 2025
College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar.
Tumor necrosis factor alpha inhibitors (TNFi) are biologic drugs that target TNFα, a key pro-inflammatory cytokine, to suppress disease activity and alleviate symptoms of various autoimmune diseases, including inflammatory bowel disease. This review focuses on the five US FDA-approved TNFi including the monoclonal antibodies Infliximab, Adalimumab, Golimumab, Certolizumab pegol and the soluble TNFα receptor fusion protein Etanercept, with a brief mention of other available biosimilars to TNFi. The review aims to summarize the recent evidence on the pharmacokinetics, pharmacodynamics, and pharmacogenomics of TNFi with a particular focus on Human Leukocyte Antigen (HLA) variants in terms of their genetic contribution to the response to TNFi.
View Article and Find Full Text PDF